The liver is the key organ involved in systemic inflammation, but the relation between hepatic inflammation and atherogenesis is poorly understood. Since nuclear factor-κB (NF-κB) is a central regulator of inflammatory processes, we hypothesized that chronically enhanced hepatic NF-κB activation, through hepatocyte-specific expression of IκB kinase-β (IKKβ) (LIKK), will aggravate atherosclerosis development in APOE*3-Leiden (E3L) mice. E3L.LIKK and E3L control littermates were fed a Western-type diet for 24 weeks. E3L.LIKK mice showed a 2.3-fold increased atherosclerotic lesion area and more advanced atherosclerosis in the aortic root with less segments without atherosclerotic lesions (11 vs. 42%), and more segments with mild (63% vs. 44%) and severe (26% vs. 14%) lesions. Expression of LIKK did not affect basal levels of inflammatory parameters, but plasma cytokine levels tended to be higher in E3L.LIKK mice after lipopolysaccharide (LPS) administration. E3L.LIKK mice showed transiently increased plasma cholesterol levels, confined to (V)LDL. This transient character resulted in a mild (+17%) increased cumulative plasma cholesterol exposure. We conclude that selective activation of NF-κB in hepatocytes considerably promotes atherosclerosis development which is (at least partly) explained by an increased sensitivity to pro-inflammatory triggers and transiently increased plasma cholesterol levels.
Introduction
Increased inflammation, in addition to disturbances in lipid metabolism, is the other main contributor to the development of atherosclerosis. 1 Nuclear factor-κB (NF-κB) has been identified as the most important transcription factor in the regulation of inflammatory processes during atherosclerosis development. 2 In unstimulated cells, NF-κB p65/p50 dimer is kept inactive by its inhibitory protein: inhibitor of κB (IκB). A wide range of extracellular stimuli, including cytokines, microbial components, and also free fatty acids, induce activation of the IκB kinase complex, which consists of two kinases (IKKα and -β) and a regulatory subunit, NEMO/IKKγ. This complex mediates the phosphorylation of IκB, resulting in its ubiquitination and degradation, leaving the NF-κB dimer free to translocate to the nucleus and activate its target genes. 2 While general inhibition of the NF-κB pathway by pharmacological agents reduces atherosclerosis development in mice, 3, 4 the relative contribution of NF-κB may differ at cellular-or tissue-specific level. Suppression of the NF-κB pathway in endothelial cells by ablation of NEMO/IKKγ has been shown to decrease atherosclerosis development. 5 In murine bone marrow transplantation models, inhibition of the NF-κB pathway at distinct levels in hematopoietic cells can have different outcomes, i.e. deficiency of the NF-κB p50 subunit resulted in smaller atherosclerotic lesions, 6 whereas deletion of IKKβ increased atherosclerosis development.
7 Surprisingly, the role of the NF-κB pathway in hepatocytes on atherosclerosis development has not been investigated thus far.
The liver plays a central role in both lipid metabolism 8 and inflammation. 9 Disturbances in lipid metabolism and increased inflammation are the two main risk factors for atherogenesis. 1 Hepatocytes form the largest population of cells in the liver and execute most of its important functions. During inflammation, acute phase proteins are mainly synthesized by the hepatocytes. 10 Interestingly, hepatocyte-specific deficiency of gp130, a receptor component of IL-6 signaling which signals independent of the NF-κB pathway, decreases atherosclerosis in apoe -/-mice, 11 suggesting that reduced hepatic inflammation is associated with less atherosclerosis development.
Despite ample evidence implicating the involvement of NF-κB in atherogenesis, the hepatocyte-specific role of NF-κB in atherosclerosis has not been investigated directly. Therefore, in this study we aimed to investigate whether chronic activation of hepatocytespecific NF-κB aggravates atherosclerosis development. We used transgenic mice with hepatocyte-specific expression of human IKKβ (Liver-specific IKKβ or LIKK mice), resulting in an increase of active NF-κB, 12 crossbred with atherosclerosis-prone APOE*3-Leiden (E3L) mice. E3L mice exhibit a human-like lipoprotein distribution on a cholesterol-rich diet due to transgenic expression of a human mutant of the APOE3 gene, and are therefore susceptible to atherosclerosis development. 13 Collectively, our results show that hepatocyte-specific NF-κB activation markedly aggravates atherosclerosis development in E3L mice.
Hepatic Inflammation Aggravates Atherosclerosis

Methods
Animals and study design
Transgenic LIKK mice expressing constitutively active human IKKβ in the hepatocytes by an albumin promoter 12 were crossbred with E3L mice 14 to generate heterozygous E3L.LIKK and control E3L littermates, as described before. 15 Mice were housed under standard conditions with a 12-hour light/dark cycle and had free access to food and water. Female mice of 10-12 weeks of age were fed a Western-type diet containing 15% (w/w) cacao butter supplemented with 0.25% (w/w) cholesterol (Hope Farms, Woerden, The Netherlands). Food intake and body weight were measured weekly. Unless indicated otherwise, blood was drawn every 4 weeks after 4 hours of fasting in EDTA-containing tubes by tail bleeding, and plasma was isolated by centrifugation. All animal experiments were approved by the Institutional Ethical Committee on Animal Care and Experimentation of the Leiden University Medical Center (Leiden, The Netherlands).
mRNA expression analysis
Total RNA from livers of E3L and E3L.LIKK mice was isolated using an RNA isolation kit according to manufacturer's specifications, including a 15 min. DNAse I treatment (Macherey-Nagel, Düren, Germany). Quality control of the isolated RNA was checked with the lab-on-a-chip technology using Experion Stdsens analysis kit (Bio-Rad, Hercules, CA). One µg of total RNA was converted to cDNA with iScript cDNA Synthesis kit (Bio-Rad) and purified with Nucleospin Extract II kit (Macherey-Nagel, Düren, Germany). Real time PCR (RT-PCR) was carried out on an iQ5 Single-Color real-time PCR detection system (Bio-Rad) using the Sensimix SYBR Green RT-PCR mix (Quantace, London, UK). Expression levels were normalized using hypoxanthineguanine phosphoribosyl transferase (Hprt), cyclophilin (Cyclo) and glyceraldehyde 3-phosphate dehydrogenase (Gapdh). Primer sequences are listed in Supplemental Table 1 .
Western blot analysis
Liver tissue was homogenized by Ultraturrax (22,000 rpm; 2x5 sec) in an ice-cold buffer (pH 7.4) containing 30 mM Tris.HCl, 150 mM NaCl, 10 mM NaF, 1 mM EDTA, 1 mM Na 3 VO 4 , 0.5% (v/v) Triton X-100, 1% (v/v) SDS and protease inhibitors (Complete, Roche, Mijdrecht, The Netherlands) at a 1:6 (w/v) ratio. Homogenates were centrifuged (16,000 rpm; 15 min., 4°C) and the protein content of the supernatant was determined using the BCA protein assay kit (Pierce, Rockford, IL). Proteins (20-50 µg) were separated by 7-10% SDS-PAGE followed by transfer to a polyvinylidene fluoride membrane. Membranes were blocked for 1 hour at room temperature in Tris-buffered saline with Tween-20 with 5% non-fat dry milk followed by an overnight incubation with either IKKβ (ab32135, Abcam, Cambridge, UK), tubulin, pSer536 NF-κB p65 or NF-κB p65 antibodies (#2148, #3031, #3034, resp., Cell Signaling, Danvers, MA). Blots were then incubated with horseradish peroxidase-conjugated secondary antibodies for 1 hour at room temperature. Bands were visualized by enhanced chemiluminescence and quantified using Image J software (NIH, USA).
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Plasma inflammatory markers
Plasma levels of serum amyloid A (SAA) were determined using the murine Phase Serum Amyloid A Assay kit (Tridelta, County Kildare, Ireland) according to manufacturer's instructions. Plasma levels of inflammatory cytokines and chemokines (IFNγ, IL-12 p70, IL-1β, IL-6, TNFα and IL-10) were measured using a multiplex murine inflammatory cytokine profile immunoassay from Meso Scale Discovery (MSD) on a MSD 2400 plate reader according to the manufacturer's protocol (MSD, Gaithersburg, MD).
Lipopolysaccharide stimulation
Mice were injected i.v. with Salmonella minnesota Re595 lipopolysaccharide (LPS) (SigmaAldrich, St. Louis, MO) (50 mg/kg body weight). Blood was collected 90 min. after injection in heparin-coated capillaries. Plasma was assayed for cytokines as described above.
FACS staining of leukocyte subpopulations in peripheral blood
Nonfasted, whole blood was drawn in EDTA-containing tubes by tail bleeding and incubated with antibodies against Ly6C-FITC (kindly provided by dr P.J. Leenen, Erasmus University, Rotterdam, The Netherlands), Ly6G-PE, CD115-biotin and CD11b-APC (all from Pharmingen, Alphen a/d Rijn, The Netherlands). In between all steps, cells were washed with PBS containing 1% BSA and 0.05% Na-azide.
Binding of anti-CD115-biotin was detected with streptavidin conjugated with PerCP-Cy5.5 (Pharmingen, Alphen a/d Rijn, The Netherlands). Red blood cells were lysed with shock-buffer, cells were fixed with 1% paraformaldehyde and measured with an LSRII (Becton Dickinson, Erembodegem, Belgium).
To obtain leukocyte profiles, the following gating strategy was applied: debris was gated out in a forward (FSC)/side scatter (SSC) plot and leukocytes minus debris were divided according to their CD11b expression (myeloid lineage: CD11b-pos; lymphoid lineage: CD11b-neg). CD11b-pos cells were then selected and using Ly6G expression and SSC, cells were divided in neutrophilic granulocytes (Ly6G-hi/SSC-hi), eosinophilic granulocytes (Ly6G-neg/SSC-hi) and a non-granulocyte population (Ly6G-neg/SSC-low). The non-granulocyte population was then selected and using their CD11b and CD115 expression, monocytes (CD11b-pos/CD115-pos) and NK cells (CD11b-med/CD115-neg) were identified. Next, the monocyte population was selected and using Ly6C expression and FSC, classical monocytes (Ly6C-hi/FSC-low), nonclassical monocytes (Ly6C-low/FSC-low) and intermediate monocytes (Ly6C-med/FSC-low) were identified. Going back to the lymphoid lineage (CD11b-neg cell population), using Ly6C-expression, lymphocytes (Ly6C-low/FSC-low) and lymphoblasts (Ly6-ly6C-med/FSC-hi) were identified.
Plasma lipids, lipoprotein profile, hepatic VLDL-TG production and liver lipids analysis Plasma total cholesterol (TC), triglycerides (TG) and phospholipids (PL) levels were determined using enzymatic kits from Roche Molecular Biochemicals (Woerden, The Netherlands) according to the manufacturer's protocols. We used the following formula to calculate the cumulative plasma TC levels over 24 weeks of Western-type diet feeding which equals the area Hepatic Inflammation Aggravates Atherosclerosis under the curve for the plasma TC in time: 4*TC t=0 + 0.5*4*(TC t=4 -TC t=0 ) + 4*TC t=4 + 0.5*4*(TC t=8 -TC t=4 ) + 4*TC t=8 + 0.5*4*(TC t=12 -TC t=8 ) + 4*TC t=12 + 0.5*4*(TC t=16 -TC t=12 ) + 4*TC t=16 + 0.5*4*(TC t=20 -TC t=16 ) + 4*TC t=20 + 0.5*4*(TC t=24 -TC t=20 ). The correlation between cumulative plasma TC level and atherosclerotic lesion area was assessed for both E3L and E3L.LIKK mice. For the determination of lipid distribution over plasma lipoproteins, pooled plasma per group was size-fractionated using an ÄKTA fast performance liquid chromatography (FPLC) system (Pharmacia, Roosendaal, The Netherlands). Each sample was injected onto a Superose 6 HR3.2/30 column and eluted at a constant flow rate of 50 µL/min in PBS, pH 7.4. Fractions of 50 µL were collected and assayed for TC as described above.
Mice were fasted for 4 hours prior to the start of the hepatic VLDL-TG production experiment, and, subsequently, sedated with 6.25 mg/kg acepromazine (Alfasan), 6.25 mg/kg midazolam (Roche), and 0.3125 mg/kg fentanyl (Janssen-Cilag). At timepoint zero, blood was taken via tail bleeding and mice were i.v. injected with 100 µL PBS containing 100 µCi Trans 35 S label to measure de novo total apolipoprotein B (apoB) synthesis. After 30 min., the animals received 500 mg of tyloxapol (Triton WR-1339, Sigma-Aldrich) per kg body weight as a 10% (w/w) solution in sterile saline, to prevent systemic lipolysis of newly secreted hepatic VLDL-TG. 16 Additional blood samples were taken at regular timepoints after tyloxapol injection and used for determination of plasma TG concentration. At timepoint 120 min., the animals were sacrificed and blood was collected by orbital puncture for isolation of VLDL by density gradient ultracentrifugation. 17 35 S-labeled total apoB content was measured in the VLDL fraction after precipitation with isopropanol. 18 Lipids from liver tissue were extracted according to a protocol adapted from Bligh and Dyer. 19 Hepatic TG, PL concentrations were determined using the enzymatic kits as described previously. TC, free cholesterol (FC) and cholesteryl ester (CE) content were assessed with a cholesterol/cholesteryl ester quantitation enzymatic kit according to manufacturer's specifications (Biovision Research Products, Mountain View, CA). Liver lipids were expressed per mg protein, which was measured using the BCA protein assay kit (Pierce, Rockford, IL).
Atherosclerosis quantification
Mice were euthanized by carbon dioxide inhalation after 24 weeks of diet. Hearts were isolated and fixed in 4% paraformaldehyde, dehydrated and embedded in paraffin, and were crosssectioned (5 µm) throughout the entire aortic root area. Of each mouse, 4 sections with 50-µm intervals were used for quantification of atherosclerotic lesion area. Characterization of lesion severity was performed separately in each of the 3 segments between the aortic valves in the 4 sections. 20 Sections were stained with hematoxylin-phloxine-saffron (HPS). Atherosclerotic lesions were categorized for severity by one blinded observer, according to the guidelines of the American Heart Association, adapted for mice. Various types of lesions were distinguished: type 0 (no lesions) (Supplemental Fig. 8A ), type I to III (early fatty streak-like lesions containing foam cells) (Supplemental Fig. 8B-D) , and type IV to V (advanced lesions containing foam cells in the media, presence of fibrosis, cholesterol clefts, mineralization, and/or necrosis) (Supplemental Fig. 8E-F) .
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Immunohistochemistry for determination of adhering monocytes and macrophage-, and smooth muscle cell content in the lesions was performed as described previously. 21, 22 The sections were incubated overnight with antibody M18 (1:100, Santa Cruz Biotechnology, Santa Cruz, Calif) and, subsequently, with biotinylated rabbit anti-goat conjugate (1:400, Brunschwig chemie, Amsterdam, The Netherlands) for quantification of MCP-1. AIA 31240 rabbit antiserum (1:1000, Accurate Chemical and Scientific, Westbury, NY) in combination with biotinylated donkey anti-rabbit conjugate (1:3000, Amersham Pharmacia Biotech) were used for quantification of both the number of monocytes adhering to the endothelium as well as the macrophage area. Antibody M0851 (1:800, Dako, Carpinteria, CA) and biotinylated horse anti-mouse conjugate (1:400, Vector Laboratories, Burlingame, CA) were used to quantify smooth muscle actin. Immunostaining was amplified using Vector Laboratories Elite ABC kit (Vector Laboratories, Burlingame, CA) and the immunoperoxidase complex was visualized with Nova Red (Vector Laboratories, Burlingame, CA). Counterstaining was performed with Mayer's hematoxylin. Sirius red was used to stain for collagen in the lesions (Chroma, Stuttgart, Germany).
Total lesion size, MCP-1-, macrophage-, smooth muscle cell-, and collagen content were quantified using Cell^D image analysis software (Olympus Soft Imaging Solutions, Münster, Germany).
Statistical analysis
Data are presented as means ±SEM. SPSS 17.0 for Windows (SPSS, Chicago, Ill) was used for statistical analysis. Statistical differences were assessed with the Mann-Whitney U test. For lesion typing, differences were determined by the χ 2 test. To assess the correlation between cumulative cholesterol exposure and atherosclerotic lesion area, the Pearson correlation test was performed after log transformation of the atherosclerotic lesion area. Differences at P<0.05 were regarded as statistically significant.
Results
LIKK causes low-grade inflammation
The overall appearance of E3L and E3L.LIKK mice during the study was similar. To assess whether expression of LIKK affects body weight gain, we measured food intake and body weight weekly. Both were not different between E3L.LIKK and E3L control mice (Supplemental Fig. 1A-B) . The liver-and spleen weight and histological morphology of the liver were also comparable between E3L.LIKK and E3L mice (data not shown). To gain more insight in the effects of LIKK on inflammation, we determined whether LIKK expression increased the inflammatory state of the liver and systemic inflammatory markers in E3L.LIKK mice on a Western-type diet. We confirmed previous findings 15 showing that the enhanced expression of hepatocyte-specific human IKKβ (Supplemental Fig. 2A ) resulted in a 1.4-fold increased hepatic NF-κB activation, as shown by an increase in the phosphorylated p65 subunit (pNF-κB Ser536 ) (Supplemental Fig. 2B ). IKKβ kinase phosphorylates subunit p65 of NF-κB at the position Ser536, which activates the transcriptional activity of NF-κB. 23 The transgenic expression of human IKKβ mRNA was present only in E3L.LIKK mice and did not alter murine IKKβ mRNA expression (Supplemental Fig. 2C-D) . The enhanced Hepatic Inflammation Aggravates Atherosclerosis hepatic NF-κB activation in E3L.LIKK mice did not result in increased IL-6 expression in whole liver, but did result in a tendency towards increased IL-1β expression (P=0.085) and a significant increase in MCP-1 expression (Supplemental Table 2 ).
To evaluate whether the increased hepatocyte-specific NF-κB activation in E3L.LIKK mice enhanced the systemic inflammatory state, we determined the plasma inflammation marker SAA and plasma cytokines under basal conditions. LIKK expression did not affect SAA before (3.1 ±0.17 vs. 3.4 ±0.15 µg/mL) and after 8 weeks (4.4 ±0.28 vs. 4.2 ±0.31 µg/mL) and 24 weeks (4.9 ±0.51 vs. 5.4 ±0.78 µg/mL) of Western-type diet feeding ( Fig. 1) , and neither the determined plasma cytokine levels (Supplemental Fig. 3A-F) . SAA levels increased with Western-type diet feeding in both E3L and E3L.LIKK mice, but this difference only reached statistical significance in E3L.LIKK mice (Fig. 1 ).
Since we did not observe a clear increased systemic pro-inflammatory state under basal conditions, we challenged the mice with LPS to boost the inflammatory response. Interestingly, after injection of LPS, pro-inflammatory cytokines (e.g. IL-1β, IFNγ) showed a tendency towards increased plasma levels in E3L.LIKK mice as compared to E3L mice ( Fig. 2A-F) . The antiinflammatory IL-10:IL-1β ratio was significantly lower in E3L.LIKK mice (Fig. 2G) . Overall, these data indicate that E3L.LIKK mice are more sensitive to pro-inflammatory triggers compared to their E3L littermates.
To study whether this chronic low-grade inflammation in E3L.LIKK mice also resulted in increased inflammatory cell counts in liver and plasma, we determined the hepatic mRNA expression of various cell-type markers of inflammatory cells present in the liver, which are likely to influence atherogenesis, 24 and the number of circulating monocytes. Hepatic mRNA expression of CD68 (Kupffer cells), CD3 ((NK)T cells), and Vα14 (NKT cells) were not different between the genotypes (Supplemental Table 2 ), neither were the total number of circulating monocytes, the pro-inflammatory Ly6C-hi monocyte subset, the intermediate Ly6C-med monocyte subset and the less inflammatory Ly6C-lo monocyte subset (Supplemental Fig. 4A-D) . Together, the above findings indicate that the enhanced hepatocyte-specific NF-κB activation in E3L.LIKK mice results in a tendency towards a mildly enhanced hepatic pro-inflammatory state and an elevated sensitivity to pro-inflammatory stimuli as compared to E3L littermates.
LIKK transiently enhances VLDL cholesterol levels
To assess the effect of hepatocyte-specific NF-κB activation on plasma lipid levels, TC, TG and PL concentrations were determined every 4 weeks in E3L.LIKK and E3L mice. LIKK expression caused a transient increase of plasma TC levels only at 8 weeks (+50%; P<0.0001) and 12 weeks (+28%; P<0.05) of Western-type diet feeding (Fig. 3A) . Accordingly, the cumulative total cholesterol exposure was higher in E3L.LIKK than in E3L mice (+17%; P<0.05; Fig. 3B ). A similar transient increase was found for plasma TG and PL levels (Supplemental Fig. 5A-B) .
To determine which lipoproteins contribute to the transient elevated plasma TC levels, lipoproteins were size-fractionated by FPLC, and cholesterol was measured in the individual fractions. The transient increase in plasma TC levels at 8 weeks of Western-type diet feeding in E3L.LIKK mice was confined to (V)LDL, whereas at 16 weeks the lipoprotein distribution in the E3L.LIKK mice was similar to that of the E3L mice, in line with the plasma lipid levels (Fig. 3C) . Consistent with our previous finding that expression of LIKK increased the VLDL production in male mice on chow diet, 15 we found that expression of LIKK increased, albeit not significantly, the VLDL-TG production rate (+24%) (Supplemental Fig. 6A ), and tended to increase the VLDLapolipoprotein B (apoB) production rate (+33%) (Supplemental Fig. 6B ). No differences were observed in the liver lipid content between E3L.LIKK and E3L mice (Supplemental Fig. 7A-E) . Taken together, these findings indicate that hepatocyte-specific NF-κB activation results in a modest and transient increase in plasma lipid levels in E3L mice. 
LIKK enhances atherosclerosis development
To investigate the effect of LIKK expression on atherosclerosis development, E3L.LIKK and E3L mice were sacrificed after 24 weeks of Western-type diet feeding, and lesion size and severity were measured in the aortic root. Representative pictures of both groups are shown in Fig. 4A . E3L.LIKK mice developed more than 2-fold larger atherosclerotic lesions (+131%; P<0.05; Fig. 4B ) as compared to their E3L littermates. This increased lesion area coincided with more advanced lesion progression, since we found markedly fewer segments without atherosclerotic lesions (11% vs. 42%; P<0.001) and more segments with mild (63% vs. 44%; P<0.001) and severe lesions (26% vs. 14%; P<0.001) as compared to E3L mice (Fig. 4C) . Examples of mild and severe lesions are shown in Supplemental Figure 8 . These data indicate that chronic hepatocyte-specific NF-κB activation severely augments atherosclerosis development in E3L mice.
LIKK aggravates atherosclerotic lesion composition
We next evaluated whether LIKK expression would affect monocyte adherence and recruitment to the vascular wall, as well as the composition of the atherosclerotic lesions with respect to the macrophage, smooth muscle cell, and collagen content of the lesions. Adherence of monocytes to the vessel wall and the content of the chemokine monocyte chemoattractant protein-1 (MCP-1) of the atherosclerotic lesions were not significantly enhanced in E3L.LIKK mice as compared to E3L mice ( Fig. 5A-B) . LIKK expression did not affect the relative macrophage and collagen content of the lesions (Fig. 5C+E ), but did result in an increased smooth muscle cell content of the lesions (+79%, P<0.05; Fig. 5D ).
Aggravated atherosclerosis development in E3L.LIKK mice does not solely depend on the transient increase in plasma cholesterol levels
In E3L mice on Western-type diet, the cumulative plasma cholesterol exposure is highly predictive for the atherosclerotic lesion area (unpublished data, J.F.P. Berbée, P.C.N. Rensen). To verify if the transient increase in plasma TC levels (Fig. 3 ) alone could account for the aggravation in atherosclerosis development observed in E3L.LIKK mice, or whether additional mechanism(s) could contribute, including the low-grade systemic inflammation, we assessed the correlation between the cumulative plasma total cholesterol exposure and the atherosclerotic lesion area of the E3L.LIKK and E3L mice. As expected, there was a significant positive logarithmic correlation Chapter 3 between the atherosclerotic lesion area and the cumulative plasma cholesterol exposure in the control E3L mice (Supplemental Fig. 9A ; r 2 =0.757, P=0.002). However, we did not observe such a correlation in the E3L.LIKK mice (Supplemental Fig. 9B ; r 2 =-0.250, P=0.369), indicating that in addition to the transient increase in plasma TC levels in E3L.LIKK mice, additional mechanism(s), most likely the increased sensitivity to pro-inflammatory stimuli, contributed to the aggravated atherosclerosis development in these mice.
Discussion
NF-κB is regarded as a potential therapeutic target in atherosclerosis 3, 4 and studying tissue-and cell-specific effects of NF-κB in atherogenesis will expand our knowledge in the comprehensive actions of NF-κB on atherosclerosis development. The present study demonstrates for the first time that chronic, hepatocyte-specific expression of IKKβ (LIKK) and subsequent activation of NF-κB aggravates atherosclerosis development in E3L mice. In addition, the atherosclerotic lesion composition with respect to the macrophage and collagen content was not affected by LIKK, but in line with the presence of more advanced lesions, the smooth muscle cell content was increased. Expression of LIKK resulted in transiently increased plasma cholesterol levels and an enhanced sensitivity to pro-inflammatory triggers, which both are likely to have contributed to the increased atherosclerotic lesion size and severity. Since lesion size and severity are often correlated in atherosclerosis studies with different murine models, 13 , 25 the increased lesion severity in E3L.LIKK mice is likely to be mainly attributed to the larger size of the lesions.
Expression of LIKK in E3L mice increased the activation of the NF-κB pathway in the liver, in line with our previous report. 15 In addition, hepatic mRNA expression of inflammatory parameters was increased or tended to be increased in E3L.LIKK mice, indicating that inflammatory mediators at local tissue level were enhanced in E3L.LIKK mice. This enhanced activation of hepatocyte-specific NF-κB in E3L.LIKK mice, however, did not result in a significant increased systemic pro-inflammatory state under basal conditions as compared to their E3L littermates. Importantly, Cai et al. 12 demonstrated that in LIKK mice on a wild-type background, systemic levels of IL-6 were only mildly elevated, while IL-1β and TNFα levels were similar as in wild-type mice. Our results show that LIKK expression on an E3L background resulted in a less pronounced hepatic inflammatory state as compared to LIKK expression on a wild-type background as described by Cai et al., 12 as reflected in a smaller increase in active NF-κB (1.4-vs. 2.2-fold) and mRNA levels of pro-inflammatory cytokines levels in the liver. Furthermore, under basal conditions E3L mice have lower levels of active NF-κB present in the liver as compared to wild-type mice (unpublished data, J.A. van Diepen, M.C. Wong, P.J. Voshol). This implies that E3L mice have a lower chronic inflammatory state than wild-type mice, which could interfere with the pro-inflammatory effects caused by expression of LIKK in the present study. Also, in comparison with other murine atherosclerosis models, e.g. the apoe -/-and ldlr -/-mice, E3L mice display a milder phenotype with respect to hyperlipidemia and increased inflammation. 26, 27 In the current study, basal circulating levels of some cytokines were at borderline of the detection limit of current assays (Supplemental Fig. 3 ) and, as expected, the cytokine levels increased approximately 5-to 3700-fold after LPS injection (Fig. 2) . Furthermore, after stimulation with Hepatic Inflammation Aggravates Atherosclerosis LPS, E3L.LIKK mice showed a tendency towards a higher systemic inflammatory state than E3L mice.
There is a strong interaction between inflammation and lipid metabolism. 28 For example, lowering inflammation using salicylate did not only reduced NF-κB activation, but concomitantly also reduced circulating cholesterol levels in E3L mice. 29 In line with this observation, in the present study we found higher plasma lipid levels at 8 weeks of Western-type diet feeding in female E3L.LIKK compared to E3L mice, which were confined to (V)LDL. We hypothesize that the increased lipid levels at this time point are accompanied by increased systemic inflammation, which is in line with previous findings showing that lipid metabolism and inflammation strongly influence each other. 28 A possible cause for the increased plasma lipid levels at 8 weeks of diet is therefore a more enhanced inflammation in the liver, possibly due to an increased activation of the NF-κB pathway in the liver.
We recently reported that male E3L.LIKK mice on chow diet also showed enhanced (V)LDL levels as a result of an increased hepatic VLDL-TG production rate, 15 and found in the current study a trend towards an enhanced VLDL-apoB production in female E3L.LIKK mice on Westerntype diet, with a similar effect-size. Possible reasons for the less apparent increase of VLDL-TG production in females compared to males are differences in gender and/or diet. Although the increase in VLDL-TG production is more apparent in male E3L.LIKK mice, we used female mice in the present study. The main reason for this is that female E3L mice are more susceptible to develop atherosclerosis. In order for male E3L mice to become similarly atherosclerosisprone they need to be fed Western-type diets not only with higher percentages of cholesterol, but also containing cholate. In addition, fructose was added to the drinking water to further raise their (V)LDL-cholesterol levels. 30 The increase in (V)LDL levels in females in the current study was only transient at 8 weeks of Western-type diet feeding and disappeared at 16 weeks. Since no differences in plasma lipid levels and hepatic mRNA expression of genes involved in lipid metabolism were detected between both groups at 24 weeks of diet, the increased VLDL-TG production at 8 weeks of diet is likely to be transient. At present, we cannot explain the transient nature of this increase in (V)LDL levels, but it may be the result of a progressive negative feedback mechanism to reduce the hepatic VLDL production which takes place during long-term Western-type diet feeding.
Dyslipidemia is regarded as the classical risk factor for atherosclerosis development. The transiently enhanced total cholesterol levels, resulting in a modest increase (+17%) in cumulative total cholesterol exposure upon LIKK expression, thus likely contributed to the enhanced atherosclerosis development. Previous diet-induced atherosclerosis studies in E3L mice have consistently demonstrated that there is a positive logarithmic relation between the cumulative cholesterol exposure during the study and the atherosclerotic lesion area (J.F.P. Berbée, P.C.N. Rensen, unpublished data). In agreement with these previous observations, we did observe such a significant logarithmic relation in E3L mice but not in E3L.LIKK mice. This suggests that the increase in atherosclerotic lesion area in E3L.LIKK mice can only partly be attributed to the transiently enhanced plasma cholesterol levels and that additional mechanisms are involved.
Inflammation is the second main risk factor for atherosclerosis. Enhanced extravascular or systemic inflammation, by the periodontal pathogen Porphyromonas gingivalis 31 or by repeated Chapter 3 administration of LPS, 21 respectively, promotes atherosclerosis development. In addition, in humans, low-grade systemic inflammation is associated with enhanced risk of coronary artery disease. 32, 33 It is thus likely that, as discussed above, the increased sensitivity for proinflammatory triggers such as LPS in E3L.LIKK mice also directly contributed to the enhanced atherosclerotic lesion formation.
We excluded higher circulating levels of pro-inflammatory Ly6C-hi monocytes as being another possible contributor to the aggravated atherosclerosis development in E3L.LIKK mice. Adhesion of monocytes to endothelial cells and subsequent migration into the vessel wall is one of the crucial steps in atherosclerotic lesion formation. Ly6C-hi monocytes are more prone to adhere to activated endothelium than Ly6C-lo monocytes and are, therefore, associated with enhanced atherosclerosis development. 34 We found that E3L.LIKK mice had similar levels of circulating subsets of monocytes as compared to their E3L controls, which is consistent with the observed similar number of adhering monocytes to the vascular wall.
In line with the enhanced atherosclerosis development that we observed in E3L.LIKK mice, Luchtefeld et al. 11 have reported that gp130-deficient mice with defective IL-6 signaling specifically in hepatocytes, develop less atherosclerosis, indicating that modulation of hepatic inflammation can have profound effects on atherogenesis. These studies also underscore that enhanced inflammation in the liver, e.g. due to viral hepatitis or steatohepatitis, may augment atherosclerosis development. Indeed, in several clinical studies, such hepatic pathological conditions are associated with an elevated occurrence of CVD. 35, 36, 37 Even after adjustment for classical risk factors for CVD, such as LDL cholesterol levels, chronic hepatitis C infection was still significantly associated with increased atherosclerosis in a cross-sectional study. 37 Together, these findings suggest that there is a direct effect of hepatic inflammation on atherosclerosis development, independent of systemic lipid levels. Moreover, they suggest that in addition to the currently used lipid-targeted drugs such as statins, reducing NF-κB activity in the liver may be a promising additive therapeutic strategy against atherosclerosis development.
In conclusion, we have shown that hepatocyte-specific activation of NF-κB leads to larger and more advanced atherosclerotic lesions. Our studies furthermore suggest that both the transient elevated (V)LDL cholesterol levels as well as the increased sensitivity to proinflammatory stimuli are most likely responsible for this aggravating effect on atherosclerosis. These findings contribute to the present understanding of the role of the liver, and more specifically the role of hepatic NF-κB, in atherosclerosis development and may help to develop new innovative anti-atherosclerotic strategies.
Hepatic Inflammation Aggravates Atherosclerosis
Supplemental Table 2 . Expression of LIKK increases hepatic MCP-1 expression.
Target
E3L E3L.LIKK Significance
Cytokines and chemokines IL-1β 1.00 ± 0.05 1.24 ± 0.14 P = 0.085 IL-6
1.00 ± 0.13 1.24 ± 0.20 n.s. Chapter 3
Supplemental Fig. 6 . Expression of LIKK tends to increase VLDL-apoB production. After 8 weeks of Western-type diet, E3L.LIKK (black bars) and E3L mice (white bars) were fasted 4 hours and injected with Trans35S and tyloxapol, and blood samples were drawn after tyloxapol injection. The rate of TG production was calculated from the slopes of the curves from the individual mice (A). After 120 min, the total VLDLfraction was isolated by ultracentrifugation, 35 S-activity was counted, and the production rate of newly synthesized VLDL- 35 S-apoB was determined (B). Values are means ±SEM; n=5-11/group. Expression of LIKK tends to increase VLDL-apoB production. After 8 weeks of Western-type diet, E3L.LIKK (black bars) and E3L mice (white bars) were fasted 4 hours and injected with Trans35S and tyloxapol, and blood samples were drawn after tyloxapol injection. The rate of TG production was calculated from the slopes of the curves from the individual mice (A). After 120 min, the total VLDL-fraction was isolated by ultracentrifugation, 35 S-activity was counted, and the production rate of newly synthesized VLDL- 35 Supplemental Fig. 9 . Correlation between cumulative plasma TC exposure and atherosclerotic lesion area. The correlation between the cumulative plasma TC exposure and atherosclerotic lesion area, after log transformation, in E3L (open circles) (A) and the E3L.LIKK mice (closed circles) (B) was determined using the Pearson correlation test. n=15/group.
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